Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors ...(that speak only as of the date of this r...),Health

This press release includes Onyx's expectation regarding a non-GAAP financial measure of profit (non-GAAP net income or loss) and excludes the impact of employee stock-based compensation expense. Onyx's management uses non-GAAP financial measures to monitor and evaluate its operating results and trends on an on-going basis and internally for operating, budgeting and financial planning purposes. Onyx management excludes the effects of employee stock-based compensation because of varying available valuation methodologies, subjective assumptions and the variety of award types; such exclusion facilitates comparisons of its operating results to its peer companies. Onyx management believes non-GAAP information is useful for investors by offering them the ability to better identify trends in its business and better understand how management evaluates its business. Non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Onyx. The non-GAAP financial measures Onyx uses are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.